in Sudan: Multidrug Resistance, Polyclonal Dissemination, and Virulence
Overview
Authors
Affiliations
The emergence and global expansion of hyper-virulent and multidrug resistant (MDR) is an increasing healthcare threat worldwide. The epidemiology of MDR is under-characterized in many parts of the world, particularly Africa. In this study, isolates from hospitals in Khartoum, Sudan, have been whole-genome sequenced to investigate their molecular epidemiology, virulence, and resistome profiles. Eighty-six were recovered from patients in five hospitals in Khartoum between 2016 and 2020. Antimicrobial susceptibility was performed by disk-diffusion and broth microdilution. All isolates underwent whole genome sequencing using Illumina MiSeq; cgMLST was determined using Ridom SeqSphere+, and 7-loci MLST virulence genes and resistomes were identified. MDR was observed at 80%, with 35 isolates (41%) confirmed carbapenem-resistant. Thirty-seven sequence types were identified, and 14 transmission clusters (TC). Five of these TCs involved more than one hospital. was the most common virulence gene detected, in addition to some isolates harbouring and . There is a diverse population of in Khartoum hospitals, harbouring multiple resistance genes, including genes coding for ESBLs, carbapenemases, and aminoglycoside-modifying enzymes, across multiple ST's. The majority of isolates were singletons and transmissions were rare.
Antimicrobial resistance containment in Africa: Moving beyond surveillance.
Anyaegbunam Z, Mba I, Doowuese Y, Anyaegbunam N, Mba T, Aina F Biosaf Health. 2025; 6(1):50-58.
PMID: 40078303 PMC: 11894975. DOI: 10.1016/j.bsheal.2023.12.003.
Genetic Insights on Meropenem Resistance Concerning Clinical Isolates.
Elkady F, Badr B, Alfeky A, Abdulrahman M, Hashem A, Al-Askar A Life (Basel). 2024; 14(11).
PMID: 39598206 PMC: 11595234. DOI: 10.3390/life14111408.
Gamaleldin P, Alseqely M, Evans B, Omar H, Abouelfetouh A BMC Genomics. 2024; 25(1):983.
PMID: 39434011 PMC: 11492754. DOI: 10.1186/s12864-024-10661-z.
CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders.
Hussen B, Najmadden Z, Abdullah S, Rasul M, Mustafa S, Ghafouri-Fard S Cell Commun Signal. 2024; 22(1):329.
PMID: 38877530 PMC: 11179281. DOI: 10.1186/s12964-024-01713-8.
Ibrahim K, Thwood D, ELgheriani H, Salem M, Elgadiym Z, Zaghdani A Libyan J Med. 2024; 19(1):2348235.
PMID: 38718270 PMC: 11080667. DOI: 10.1080/19932820.2024.2348235.